简
/
繁
/
EN
About Us
R&D
Products
News
Careers
Investors
Contact us
News
Year
2021
2022
2023
2024
2025
Month
1
2
3
4
5
6
7
8
9
10
11
12
Boan Biotech’s Boyoujing
®
Approved for Marketing in China for the Treatment of nAMD and DME
2025.11.26
Marketing Authorization Applications for Boan Biotech’s Two Denosumab Injections Accepted in the UK
2025.11.07
BA1104 Phase III Trial in China Completes Patient Enrollment
2025.10.31
20
2025-10
Boan Biotech Presents Early Findings about BA1301 at ESMO 2025
28
2025-08
Boan Biotech Announces 2025 Half-Year Results
08
2025-08
Boyouping®, China’s First Locally Developed Dulaglutide Injection, Approved for Marketing
15
2025-07
Dr. Changlin Dou Appointed IFPMA ICH M18 Task Force Lead Expert
17
2025-06
Boan Receives FDA IND Clearance for Its CD228-Directed ADC
12
2025-06
Boan Grants Shaphar Right to Commercialize BA5101 in China
30
2025-04
Boan Biotech Presents Early Research Findings about Its Innovative Anti-CD25 Antibody (BA1106) at AACR Annual Meeting 2025
1
2
3
4
5
Follow me
鲁公网安备37069102000284